lymphocytic leukemia

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.

Out of these, 23 cases (58.97%) were of acute leukemia including both acute myeloid and acute lymphocytic leukemia; nine cases (23.07%) were of acute leukemia while eight cases (20.15%) of acute myeloid and 06 cases (15.38%) of acute lymphoblastic leukemia.

Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11

Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.

Molero et al reported a case of APL that developed two years after radiotherapy for prostate cancer in a patient with chronic lymphocytic leukemia. (11) Although no treatment was given for the patient's CLL, radiotherapy for prostate cancer in this patient might have contributed to the development of APL and is considered therapy-related.

Patients with chronic lymphocytic leukemia (CLL), the most common leukemia in the Western world, exhibit heterogeneous clinical courses and survival rates;[sup][1] some patients have an indolent disease and do not require treatment whereas others have an aggressive disease, requiring treatment at initial presentation.

Up to 8% of patients with chronic lymphocytic leukemia (CLL), including those with stable diseases, develop secondary autoimmune disorders, which can confound cytopenias, complicate the course of their CLL, compromise their quality of life, and, in some cases, be fatal [10].

BIOMARKER REPORTING TEMPLATE Chronic Lymphocytic Leukemia (CLL)

Objective: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease in terms of survival with and without treatment.

Chronic lymphocytic leukemia is a blood cancer characterized by neoplastic transformation and excess propagation of lymphocytes, a type of white blood cell, in the bone marrow.

Global Markets Direct's, 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016', provides an overview of the Chronic Lymphocytic Leukemia (CLL) pipeline landscape.

It approved sales of Venclexta (VEHN'-clecks-tah) for patients with chronic lymphocytic leukemia who relapsed or weren't helped by a prior treatment and are missing part of chromosome 17.

Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99:15524-9.